Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension

Satoshi Akagi, Kazufumi Nakamura, Hiromi Matsubara, Kengo Fukushima Kusano, Noriyuki Kataoka, Takahiro Oto, Katsumasa Miyaji, Aya Miura, Aiko Ogawa, Masashi Yoshida, Hatsue Ueda-Ishibashi, Chikao Yutani, Hiroshi Itoh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Pulmonary vascular remodeling with idiopathic pulmonary arterial hypertension (IPAH) is associated with impaired apoptosis of pulmonary artery smooth muscle cells (PASMCs). We have reported that high-dose prostaglandin I2 (PGI2) therapy markedly improved hemodynamics in IPAH patients. The therapy is thought to reverse vascular remodeling, though the mechanism is unclear. The aim of this study is to assess proapoptotic effects of PGI2 on PASMCs obtained from IPAH patients. Methods: We investigated proapoptotic effects of PGI2 in PAH-PASMCs by TUNEL assays, caspase-3,-7 assays and transmission electron microscopy. We examined the expression of Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, in PAH-PASMCs. We measured the serum FasL levels in IPAH patients treated with PGI2. Results: TUNEL-positive, caspase-3, 7-active cells and fragmentation of the nucleus were detected in PAH-PASMCs treated with PGI2. The percentage of apoptotic cells induced by PGI2 at a high concentration was higher than that induced by PGI 2 at a low concentration. PCR-array analysis revealed that PGI 2 upregulated the FasL gene in PAH-PASMCs, and we measured the FasL expression by quantitative RT-PCR and Western blotting. PGI2 significantly increased the mRNA level of FasL by 3.98 fold and the protein level of FasL by 1.70 fold. An IP receptor antagonist inhibited the induction of apoptosis, elevation of cyclic AMP and upregulation of FasL by PGI2. Serum FasL level had a significant positive correlation with PGI2 dose in IPAH patients treated with PGI2. Conclusions: PGI2 has proapoptotic effects on PAH-PASMCs via the IP receptor and upregulation of FasL.

Original languageEnglish
Pages (from-to)499-505
Number of pages7
JournalInternational Journal of Cardiology
Volume165
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Fas Ligand Protein
Epoprostenol
Pulmonary Artery
Smooth Muscle Myocytes
Up-Regulation
Apoptosis
Caspase 7
In Situ Nick-End Labeling
Caspase 3
Familial Primary Pulmonary Hypertension
Polymerase Chain Reaction
Cell Nucleus
Serum
Transmission Electron Microscopy
Cyclic AMP
Hemodynamics
Western Blotting
Cytokines

Keywords

  • Apoptosis
  • Fas ligand
  • Idiopathic pulmonary arterial hypertension
  • Prostaglandin I
  • Remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. / Akagi, Satoshi; Nakamura, Kazufumi; Matsubara, Hiromi; Fukushima Kusano, Kengo; Kataoka, Noriyuki; Oto, Takahiro; Miyaji, Katsumasa; Miura, Aya; Ogawa, Aiko; Yoshida, Masashi; Ueda-Ishibashi, Hatsue; Yutani, Chikao; Itoh, Hiroshi.

In: International Journal of Cardiology, Vol. 165, No. 3, 2013, p. 499-505.

Research output: Contribution to journalArticle

Akagi, Satoshi ; Nakamura, Kazufumi ; Matsubara, Hiromi ; Fukushima Kusano, Kengo ; Kataoka, Noriyuki ; Oto, Takahiro ; Miyaji, Katsumasa ; Miura, Aya ; Ogawa, Aiko ; Yoshida, Masashi ; Ueda-Ishibashi, Hatsue ; Yutani, Chikao ; Itoh, Hiroshi. / Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. In: International Journal of Cardiology. 2013 ; Vol. 165, No. 3. pp. 499-505.
@article{c3080f3ddc724389b9965785822db897,
title = "Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension",
abstract = "Background: Pulmonary vascular remodeling with idiopathic pulmonary arterial hypertension (IPAH) is associated with impaired apoptosis of pulmonary artery smooth muscle cells (PASMCs). We have reported that high-dose prostaglandin I2 (PGI2) therapy markedly improved hemodynamics in IPAH patients. The therapy is thought to reverse vascular remodeling, though the mechanism is unclear. The aim of this study is to assess proapoptotic effects of PGI2 on PASMCs obtained from IPAH patients. Methods: We investigated proapoptotic effects of PGI2 in PAH-PASMCs by TUNEL assays, caspase-3,-7 assays and transmission electron microscopy. We examined the expression of Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, in PAH-PASMCs. We measured the serum FasL levels in IPAH patients treated with PGI2. Results: TUNEL-positive, caspase-3, 7-active cells and fragmentation of the nucleus were detected in PAH-PASMCs treated with PGI2. The percentage of apoptotic cells induced by PGI2 at a high concentration was higher than that induced by PGI 2 at a low concentration. PCR-array analysis revealed that PGI 2 upregulated the FasL gene in PAH-PASMCs, and we measured the FasL expression by quantitative RT-PCR and Western blotting. PGI2 significantly increased the mRNA level of FasL by 3.98 fold and the protein level of FasL by 1.70 fold. An IP receptor antagonist inhibited the induction of apoptosis, elevation of cyclic AMP and upregulation of FasL by PGI2. Serum FasL level had a significant positive correlation with PGI2 dose in IPAH patients treated with PGI2. Conclusions: PGI2 has proapoptotic effects on PAH-PASMCs via the IP receptor and upregulation of FasL.",
keywords = "Apoptosis, Fas ligand, Idiopathic pulmonary arterial hypertension, Prostaglandin I, Remodeling",
author = "Satoshi Akagi and Kazufumi Nakamura and Hiromi Matsubara and {Fukushima Kusano}, Kengo and Noriyuki Kataoka and Takahiro Oto and Katsumasa Miyaji and Aya Miura and Aiko Ogawa and Masashi Yoshida and Hatsue Ueda-Ishibashi and Chikao Yutani and Hiroshi Itoh",
year = "2013",
doi = "10.1016/j.ijcard.2011.09.004",
language = "English",
volume = "165",
pages = "499--505",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension

AU - Akagi, Satoshi

AU - Nakamura, Kazufumi

AU - Matsubara, Hiromi

AU - Fukushima Kusano, Kengo

AU - Kataoka, Noriyuki

AU - Oto, Takahiro

AU - Miyaji, Katsumasa

AU - Miura, Aya

AU - Ogawa, Aiko

AU - Yoshida, Masashi

AU - Ueda-Ishibashi, Hatsue

AU - Yutani, Chikao

AU - Itoh, Hiroshi

PY - 2013

Y1 - 2013

N2 - Background: Pulmonary vascular remodeling with idiopathic pulmonary arterial hypertension (IPAH) is associated with impaired apoptosis of pulmonary artery smooth muscle cells (PASMCs). We have reported that high-dose prostaglandin I2 (PGI2) therapy markedly improved hemodynamics in IPAH patients. The therapy is thought to reverse vascular remodeling, though the mechanism is unclear. The aim of this study is to assess proapoptotic effects of PGI2 on PASMCs obtained from IPAH patients. Methods: We investigated proapoptotic effects of PGI2 in PAH-PASMCs by TUNEL assays, caspase-3,-7 assays and transmission electron microscopy. We examined the expression of Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, in PAH-PASMCs. We measured the serum FasL levels in IPAH patients treated with PGI2. Results: TUNEL-positive, caspase-3, 7-active cells and fragmentation of the nucleus were detected in PAH-PASMCs treated with PGI2. The percentage of apoptotic cells induced by PGI2 at a high concentration was higher than that induced by PGI 2 at a low concentration. PCR-array analysis revealed that PGI 2 upregulated the FasL gene in PAH-PASMCs, and we measured the FasL expression by quantitative RT-PCR and Western blotting. PGI2 significantly increased the mRNA level of FasL by 3.98 fold and the protein level of FasL by 1.70 fold. An IP receptor antagonist inhibited the induction of apoptosis, elevation of cyclic AMP and upregulation of FasL by PGI2. Serum FasL level had a significant positive correlation with PGI2 dose in IPAH patients treated with PGI2. Conclusions: PGI2 has proapoptotic effects on PAH-PASMCs via the IP receptor and upregulation of FasL.

AB - Background: Pulmonary vascular remodeling with idiopathic pulmonary arterial hypertension (IPAH) is associated with impaired apoptosis of pulmonary artery smooth muscle cells (PASMCs). We have reported that high-dose prostaglandin I2 (PGI2) therapy markedly improved hemodynamics in IPAH patients. The therapy is thought to reverse vascular remodeling, though the mechanism is unclear. The aim of this study is to assess proapoptotic effects of PGI2 on PASMCs obtained from IPAH patients. Methods: We investigated proapoptotic effects of PGI2 in PAH-PASMCs by TUNEL assays, caspase-3,-7 assays and transmission electron microscopy. We examined the expression of Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, in PAH-PASMCs. We measured the serum FasL levels in IPAH patients treated with PGI2. Results: TUNEL-positive, caspase-3, 7-active cells and fragmentation of the nucleus were detected in PAH-PASMCs treated with PGI2. The percentage of apoptotic cells induced by PGI2 at a high concentration was higher than that induced by PGI 2 at a low concentration. PCR-array analysis revealed that PGI 2 upregulated the FasL gene in PAH-PASMCs, and we measured the FasL expression by quantitative RT-PCR and Western blotting. PGI2 significantly increased the mRNA level of FasL by 3.98 fold and the protein level of FasL by 1.70 fold. An IP receptor antagonist inhibited the induction of apoptosis, elevation of cyclic AMP and upregulation of FasL by PGI2. Serum FasL level had a significant positive correlation with PGI2 dose in IPAH patients treated with PGI2. Conclusions: PGI2 has proapoptotic effects on PAH-PASMCs via the IP receptor and upregulation of FasL.

KW - Apoptosis

KW - Fas ligand

KW - Idiopathic pulmonary arterial hypertension

KW - Prostaglandin I

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=84877043148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877043148&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2011.09.004

DO - 10.1016/j.ijcard.2011.09.004

M3 - Article

VL - 165

SP - 499

EP - 505

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -